Results 91 to 100 of about 236,225 (308)

A Single‐Metal‐Doped Nanoplatform for Ferroptosis‐Driven cGAS‐STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy

open access: yesAdvanced Functional Materials, EarlyView.
The cGAS‐STING pathway boosts HCC antitumor immunity but lacks specific activation. Nanoplatform ZMRPF induces HCC ferroptosis via lipid ROS, releasing mtDNA. It synergizes with ZMRPF‐released Mn2⁺ to activate cGAS‐STING, amplifies antigen‐presenting cell activity, reverses HCC immunosuppression, and enables robust systemic antitumor immunity ...
Yuchen Zhang   +13 more
wiley   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

open access: yesAdvanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras   +6 more
wiley   +1 more source

Bioengineered Pancreatic Cancer Immunosuppressive Microenvironment Models for Screening Immunotherapies

open access: yesAdvanced Healthcare Materials, EarlyView.
Bioengineering tumor‐stroma pancreatic cancer models with potential to emulate the native immunosuppressive tumor microenvironment. Cancer‐on‐a‐bead models exhibited higher relevance for screening immunotherapies and modulating the protumoral PDAC microenvironment. ABSTRACT Pancreatic cancer is notably resistant to treatment, primarily due to its dense
Maria V. Monteiro   +4 more
wiley   +1 more source

Advances in Bioprinting to Model Immune‐Mediated Skin Diseases

open access: yesAdvanced Healthcare Materials, EarlyView.
This review explores how 3D bioprinting drives innovation in developing in vitro skin models that mimic immune‐mediated diseases. It highlights current technologies, key applications in studying skin pathologies, and emerging challenges. The review points toward future opportunities for improving disease modeling and advancing therapeutic and cosmetic ...
Andrea Ulloa‐Fernández   +4 more
wiley   +1 more source

Tratamento de hemangioma gigante com interferon alfa: relato de dois casos Treatment of giant hemangioma with interferon-alpha: report of two cases

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2007
O objetivo do trabalho é descrever o uso de interferon alfa no tratamento de pacientes com hemangioma gigante. Os autores relatam e analisam dois casos de hemangioma gigante em tratamento com interferon alfa. IBS, 3 anos, em acompanhamento no Ambulatório
Ana Julia Balau   +3 more
doaj   +1 more source

Eosinophilic dermatosis of hematologic malignancy: a case report [PDF]

open access: yes, 2020
Eosinophilic dermatosis of hematologic malignancy (EDHM) is a dermatosis characterized by tissue eosinophilia that has been previously reported as insect bite-like reaction.
Almeida, FT   +4 more
core  

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

open access: yesAdvanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales   +11 more
wiley   +1 more source

Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b1 [PDF]

open access: bronze, 2005
Jian Qiu   +5 more
openalex   +1 more source

Long-term complete response of multiple lung metastases from renal cell carcinoma induced by combination therapy with interferon alpha and UFT: a case report [PDF]

open access: yes, 1993
We report a case of long-term complete response of multiple lung metastases of renal cell carcinoma (RCC) by the combination therapy with interferon alpha (IFN alpha) and UFT.
吉田, 修   +3 more
core  

Home - About - Disclaimer - Privacy